Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (отвара нови прозор)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Извор‎: Ann Intern Med 2008;148(12):939-55.

Индекс‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (отвара нови прозор)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (отвара нови прозор)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Извор‎: Am J Hematol 2000;64(1):26-31.

Индекс‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (отвара нови прозор)

Hydroxyurea for the treatment of sickle cell anemia. (отвара нови прозор)

Platt OS.

Извор‎: N Engl J Med 2008;358(13):1362-9.

Индекс‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (отвара нови прозор)

Clinical effectiveness of decitabine in severe sickle cell disease. (отвара нови прозор)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Извор‎: Br J Haematol 2008;141(1):126-9.

Индекс‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (отвара нови прозор)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (отвара нови прозор)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Извор‎: Blood 2010;115(12):2354-63.

Индекс‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (отвара нови прозор)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (отвара нови прозор)

Hirst C, Owusu-Ofori S.

Извор‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Индекс‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (отвара нови прозор)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (отвара нови прозор)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Извор‎: Lancet Haematol 2021;8(5):e323-33.

Индекс‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (отвара нови прозор)

Sickle cell disease. (отвара нови прозор)

Meremikwu MM, Okomo U.

Извор‎: BMJ Clin Evid 2011;02:2402.

Индекс‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (отвара нови прозор)

A phase 3 trial of l-glutamine in sickle cell disease. (отвара нови прозор)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Извор‎: N Engl J Med 2018;379(3):226-35.

Индекс‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (отвара нови прозор)

Malaria chemoprophylaxis in sickle cell disease. (отвара нови прозор)

Oniyangi O, Omari AA.

Извор‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Индекс‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (отвара нови прозор)